Finshots Daily Will pharma help Kodak survive?
Aug 19, 2025
Kodak, once a photography titan, now faces a critical moment as it ventures into pharmaceuticals. The discussion highlights the company's struggle against technological shifts and its gamble on drug manufacturing for survival. Insights into this surprising pivot reveal risks and potential in the competitive pharmaceutical landscape, drawing parallels with Fujifilm's strategies. Can Kodak's transformation breathe new life into the brand? Tune in for a deep dive into this unexpected journey!
AI Snips
Chapters
Transcript
Episode notes
Kodak's Rise And Fall In Photography
- Kodak dominated cameras and film for decades, becoming synonymous with photography.
- The switch to smartphones and cloud storage removed demand for physical film and processing, triggering Kodak's decline.
Bankruptcy, Patent Sales, And A Going Concern Warning
- Kodak filed for bankruptcy in 2012 and by 2024 its revenue had fallen to about $1 billion.
- The company now warns there is 'substantial doubt' it can continue because short-term loans far exceed cash on hand.
The Immediate Cash Shortfall
- Kodak owes $477 million in short-term loans but holds only $155 million in cash.
- The company hopes a pension plan reversion of about $300 million will cover part of the gap if regulators approve it.